Diya Mitra
Overview
Explore the profile of Diya Mitra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
8
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prindle V, Richardson A, Sher K, Kongpachith S, Kentala K, Petiwala S, et al.
Nature
. 2025 Feb;
638(8052):1095-1103.
PMID: 39910291
Synthetic lethality exploits the genetic vulnerabilities of cancer cells to enable a targeted, precision approach to treat cancer. Over the past 15 years, synthetic lethal cancer target discovery approaches have...
2.
Judd A, Bawa B, Buck W, Tao Z, Li Y, Mitten M, et al.
Sci Adv
. 2024 Oct;
10(40):eado7120.
PMID: 39365864
Overexpression of the antiapoptotic protein B-cell lymphoma-extra large (BCL-X) is associated with drug resistance and disease progression in numerous cancers. The compelling nature of this protein as a therapeutic target...
3.
Chang C, Emberley E, DSouza A, Zhao W, Cosgrove C, Parrish K, et al.
Blood
. 2024 May;
144(7):757-770.
PMID: 38701407
Glucocorticoids are key components of the standard-of-care treatment regimens for B-cell malignancy. However, systemic glucocorticoid treatment is associated with several adverse events. ABBV-319 is a CD19-targeting antibody-drug conjugate engineered to...
4.
Sun N, Petiwala S, Lu C, Hutti J, Hu M, Hu M, et al.
CRISPR J
. 2019 Aug;
2:230-245.
PMID: 31436504
Genome-wide CRISPR-Cas9 essentiality screening represents a powerful approach to identify genetic vulnerabilities in cancer cells. Here, we applied this technology and designed a strategy to identify target genes that are...